The chemical chaperone PBA is a potential treatment for epilepsy patients with mutations in the SLC6A1 gene, and it has previously been shown to increase the activity of several GAT-1 variants [22], as well as that of other transporters, such as serotonin (SERT) [26], creatine (CRT1) [25] and glycine (GlyT2) [27]. This evidence concerns the gene SLC6A4 and epilepsy.